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Abstract
Background: Current prognostic gene signatures for breast cancer mainly reflect proliferation status and have limited value
in triple-negative (TNBC) cancers. The identification of prognostic signatures from TNBC cohorts was limited in the past due
to small sample sizes.
Methodology/Principal Findings: We assembled all currently publically available TNBC gene expression datasets generated
on Affymetrix gene chips. Inter-laboratory variation was minimized by filtering methods for both samples and genes.
Supervised analysis was performed to identify prognostic signatures from 394 cases which were subsequently tested on an
independent validation cohort (n=261 cases).
Conclusions/Significance: Using two distinct false discovery rate thresholds, 25% and ,3.5%, a larger (n=264 probesets)
and a smaller (n=26 probesets) prognostic gene sets were identified and used as prognostic predictors. Most of these
genes were positively associated with poor prognosis and correlated to metagenes for inflammation and angiogenesis. No
correlation to other previously published prognostic signatures (recurrence score, genomic grade index, 70-gene signature,
wound response signature, 7-gene immune response module, stroma derived prognostic predictor, and a medullary like
signature) was observed. In multivariate analyses in the validation cohort the two signatures showed hazard ratios of 4.03
(95% confidence interval [CI] 1.71–9.48; P=0.001) and 4.08 (95% CI 1.79–9.28; P=0.001), respectively. The 10-year event-free
survival was 70% for the good risk and 20% for the high risk group. The 26-gene signatures had modest predictive value
(AUC=0.588) to predict response to neoadjuvant chemotherapy, however, the combination of a B-cell metagene with the
prognostic signatures increased its response predictive value. We identified a 264-gene prognostic signature for TNBC
which is unrelated to previously known prognostic signatures.
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Introduction
Breast cancer represents a heterogeneous disease and the
currently most relevant clinical classification is based on the
expression of the estrogen receptor (ER), progesteron receptor
(PgR), as well as the human epidermal growth factor receptor 2
(HER2) [1,2]. Molecular analyses of breast cancer have led to the
introduction of molecular subtypes that largely recapitulate this
clinical classification schema [3,4] even when studies directly
comparing those two approaches for individual samples have
shown considerable discrepancies [5,6]. To develop clinically
more useful novel markers it will be necessary to study the known
subtypes separately to avoid rediscovering genes that are highly
co-expressed with ER, PgR, and HER2 [7]. The presently
available prognostic gene signatures for breast cancer mainly
reflect proliferation status and are most useful in ER-positive
cancers [4]. For triple negative breast cancers (TNBC) [8] which
lack the expression of all three receptors and represent an
aggressive disease the use of these molecular prognostic signatures
is limited.
In previous studies we demonstrated that analysis of a cohort
of only TNBC allows the identification of different molecular
phenotypes within this subtype of breast cancer [9,10]. For the
current study we assembled all publically available TNBC gene
expression datasets generated on Affymetrix gene chips to achieve the
largest possible size for prognostic marker discovery and validation.
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arrays were included and dataset-biased genes were also removed.
We partitioned the data into a discovery (i.e finding) and validation
cohort and used a supervised approach to develop prognostic
signatures. We also assessed the correlation between the resulting
prognostic predictors with 16 previously described metagenes that
can be used to categorize TNBC into molecular subsets [9,10]. The
prognostic signatures showed the highest correlation with the
Interleukin-8(IL-8)/inflammation, Vascular endothelialgrowthfactor
(VEGF), and Histone metagenes. However, the signatures did not
correlate with previously published prognostic signatures. The
majority of prognostic genes that we identified were associated with
poor prognosis, the few genes associated with good prognosis were
mainly genes that correlated with immune cell metagenes.
Materials and Methods
The REMARK recommendations for tumor marker studies
[11] were applied in all analyses of this study. The analytical
strategy and use of samples is illustrated in Figure 1, including the
number of cases used in each stage of the analysis. The R software
environment [12] (http://www.r-project.org/) and SPSS version
17.0 (SPSS Inc., Chicago, Illinois) were used for all analyses. Chi
square test was applied to assess associations between categorical
parameters. All reported P values are two sided and P#0.05 was
considered significant. An R script of the analyses is available as
Data S1 with accompanying data in an R.Data file as Data S2.
Assembly of a combined Affymetrix dataset from triple
negative breast cancers
Togenerate ahomogeneousdatasetfortheidentificationofgenes
with prognostic power among TNBC we used (i) only one array
platform (Affymetrix U133 gene chips) and (ii) included only
samples defined as triple negative based on the mRNA expression
levels of ER, PgR, and HER2 as previously described [13,14]. The
assembly of the finding cohort of 394 TNBC samples has been
reported previously [9,10]. This yielded gene expression data from
n=3488 primary breast cancers including 28 different datasets
(TableS1).ThedatawasprocessedwiththeMAS5.0algorithm[15]
of the affy package [16] of the Bioconductor software project [17].
Data from each array were log2-transformed, median-centered, and
the expression values of all the probesets from the U133A array
were multiplied by a scale factor S so that the magnitude (sum of the
squares of the values) equals one. Within this large breast cancer
dataset, 579 triple negative breast cancers (TNBC) were identified
based on the expression of ER, PgR, and HER2 from microarray
[14]. The complete normalized expression data of the 579 TNBC is
available from Gene Expression Omnibus as supplementary file,
accession number GSE31519. In addition raw microarray data of
all new samples and all relationships to re-analyzed samples are
given under this accession. Next, we calculated a comparability
metric C for each of the 579 arrays to identify the most comparable
samples. This metric C is derived from the sum of the squared
differences of the mean (m) within a specific dataset and among all
datasets, respectively, normalized by the standard deviation (s)
calculated for all genes (g) on the array:
cdataseti ~
X n
g~1
mg,dataseti {mg,total
sg,total
   2
All datasets were sorted according to this metric and the top 15
datasets with the lowest values (norm. C#0.03), corresponding to
394 samples in total, were used as the discovery cohort (Figure S1).
The remaining 185 samples with lower array comparability
together with an additional set of 76 TNBC samples that were
obtained from an independent cohort of breast cancers [18] were
used for validation (n=261) (see Figure 1).
Supervised prognostic signature generation by SAM
We applied a supervised classification method using all 22,283
probesets on the Affymetrix microarrays to identify a prognostic
gene expression signature. The Cox score option of Significance
Analysis of Microarrays (SAM) [19] using the R-package samr was
applied to the finding cohort of 297 TNBC samples with known
follow up to train the predictor. Delta values of 0.3 and 0.5 with
median false discovery rates of 25% and ,3.5%, respectively,
were used to select prognostic probesets and a compound
covariate predictor was developed that used the SAM-Score as a
weight for each corresponding probeset. For Kaplan-Meier
analysis we split the cases into quantiles of prediction scores and
plotted survival curves by quartiles and also for the highest quartile
versus all the rest.
Assessment of dataset bias among probesets with
prognostic value
Informative probesets obtained by SAM analysis were checked
for dataset bias (i.e. differential expression by dataset of origin that
would indicate laboratory-bias or sampling differences compared
to the rest). To assess dataset bias, we used Kruskal Wallis statistic
comparing the expression of each probeset with the primary
dataset vector across the 394 TNBC. Each probeset was then
tagged with that Kruskal Wallis value throughout all analyses
(Figure S5). Cutoffs for exclusion of probesets due to strong dataset
bias were derived from the distribution of the Kruskal Wallis
statistic over all datasets for each probeset (Figure S2). Those
cutoff values were used in stability analyes to validate the
robustness of the obtained results (Figure S8).
Correlation of prognostic genes with molecular
phenotypes of TNBC
To determine if the genes (i.e probesets) from the prognostic
signature correspond to or serve as surrogates for previously
describedmolecularsubtypeswithintheTNBCgroup,wecalculated
the correlation between each of the genes from the prognostic gene
lists and 16 previously established metagenes that represent different
cell populations and different molecular variants of TNBC. These
metagenes included the intrinsic genes of the basal-molecular class
[3], an apocrine/androgen receptor signalling signature [20,21], five
signatures related to different types of immune cells [22,23,24,25], a
stromal signature [26], the claudin-CD24 signature [27,28,29],
markers of blood [30] and adipocytes [3], as well as an angiogenesis
signature [31,23] and an inflammatory signature [32,33,34]. The
discovery of these metagenes was published previously [9,10] and
probeset IDs are isted in Table S2. Metagene values were calculated
as mean expression of all probesets that define the metagene. Both
the compound prognostic signature scores as well as the individual
expression of each of the probesets from the SAM lists were
correlated with the expression values of the 16 metagenes. Probesets
thatdidnotcorrelatetoanyofthemetagenesatapre-specifiedcutoff
(see Results section) were designated as ‘‘unclassified’’.
Correlation of the identified prognostic signature scores
with published gene signatures in breast cancer
The correlation of the newly identified prognostic signatures
with seven previously published prognostic signatures was
Novel Prognostic Signatures for TNBC
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between signature scores in the finding cohort of TNBC. The
following prognostic signatures were included in this analysis:
Recurrence score [35], genomic grade index [36], 70-gene
signature [37], wound response signature [38], 7-gene immune
response module [39], stroma derived prognostic predictor [40],
and a medullary like signature [18]. The genefu R-package [41,42]
was used to calculate the signature score as continuous variables
Figure 1. Development and validation of prognostic predictors according to REMARK criteria (McShane et al. J Clin Oncol.
2005;23:9067). The outline of the analysis strategy is schematically shown. The upper part shows the selection of the homogenous sample cohort
of 394 TNBC. The middle part shows the identification of prognostic genes for TNBC, the development of the prognostic predictor, and the validation
of this gene signature. The lower part displays the analysis of the genes which make up the signature regarding their relationship to previous known
molecular factors among TNBC.
doi:10.1371/journal.pone.0028403.g001
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the current TNBC-derived prognostic signatures and all other
previously described prognostic signatures and the 16 metagenes.
Survival analyses
Follow-up data was available for 297 of the 394 TNBC samples
from the finding cohort, and for 105 of the 261 samples from the
validation cohort (Table S1). All survival intervals were measured
from the time of surgery to the survival endpoint that was available
for that dataset. In 11 datasets (n=241), the end point was relapse
free survival (RFS) and in 6 other dataset (n=161) it was distant
metastasis free survival (DMFS). RFS includes local recurrences as
events whereas DMFS does not. In order to plot Kaplan-Meier
survival curves and perform survival analysis of the pooled data,
we combined both types of endpoints into a single event free
survival (EFS) endpoint that includes either RFS or DMFS
whichever is available for the particular case. We have previously
shown that the effect of using these different endpoints was rather
small in the overall dataset [14]. All results from the pooled
survival analyses were also verified by examining the effect of the
different endpoints in stratified analyses. Follow-up data for those
women in whom the survival end point was not reached were
censored at the last follow-up or at 120 months. Subjects with
missing values were excluded. We constructed Kaplan-Meier
curves and used the log-rank test to determine the univariate
significance of the variables. Cox regression analysis was applied to
analyze the univariate hazard ratio of individual metagenes as
continous variables. A Cox proportional-hazards model was used
to simultaneously examine the effects of multiple covariates on
survival. The effect of each individual variable was assessed with
the use of the Wald test and described by the hazard ratio and
95% confidence intervals (95% CI).
Predictive value of prognostic genes for response to
neoadjuvant chemotherapy in TNBC
A cohort of TNBC treated with neoadjuvant chemotherapy was
assembled for which gene expression data from pre-treatment
biopsies were available. Samples from biopsies which were
microdissected were excluded. For 191 samples from seven
datasets information on pathological complete remission (pCR)
was available (see Table S5). Receiver operator characteristics
(ROC) analyses was applied to test the value of the TNBC-derived
prognostic signatures as predictors of pathological complete
response (pCR) to neoadjuvant chemotherapy. The predictive
value of the newly identified signatures was also compared to that
of a B-cell metagene as well as a combination of both markers. We
have previously demonstrated a strong correlation of B-cell and T-
cell metagenes in breast cancers [22]. This result is in line with the
observation by our group and others that lymphocyte infiltration
in breast cancer generally represents a mixture of both B- and T-
cells [22]. Consequently both B- and T-cell metagenes carry
nearly identical information and can both be used as a surrogate
marker for infiltration of both types of lymphocytes with similar
results. Superiority of one of these markers generally results from
the specific dataset and/or cutoff point used [9,22]. In the TNBC
cohort used in this study the B-cell metagene outperformed the T-
cell metagene as a continous factor [9].
Results
Identification of prognostic markers within the subgroup
of triple negative breast cancer
The Cox score option of Significance Analysis of Microarrays (SAM)
[19] of the R-package samr was applied to the finding cohort
(n=297 samples with follow up). A delta value of 0.3 resulted in
264 prognostic probesets (235 probesets associated with poor
prognosis and 29 probesets associated with good prognosis). The
median false discovery rate (FDR) when using this delta value was
25%. A more stringent delta of 0.5 resulted in 26 probesets
associated with poor prognosis with a median false discovery rate
,3.5% (Table 1). These 26 probesets are a subset of the larger 235
probesets list (Table S9). No probesets were associated with good
prognosis at this higher stringency. The detailed results from the
SAM analysis are given in Table S3. Two distinct signatures were
constructed from the 264 and 26 probesets, respectively. The
prognostic values of both signatures were highly significant in the
finding cohort when analysed as a continous variable in
multivariate Cox regression (Table S4). Inspection of the Kaplan
Meier survival curves corresponding to the 4 prognostic score
quartiles (for both the 264- and 26-gene predictors) suggested the
highest quartile as a natural cutoff to dichotomize the patient
population (Figure S3). This cutoff was used to plot survivals
curves that are presented on Figure 2 and include the results for
both the finding and the validation cohorts. Both signatures had
strong and similar prognostic value in the discovery as well as in
the validation datasets. Table 2 includes the corresponding
multivariate Cox regression analyses of standard parameters and
the prognostic signatures. In the validation cohort the stratification
according to the 264-probeset signature resulted in a hazard ratio
(HR) of 2.76 (95% CI 1.24–6.13; P=0.013) in univariate analysis,
and HR 4.03 (95% CI 1.71–9.48; P=0.001) in multivariate
analysis (Table 2). For the 26-probeset signature, in the validation
cohort we observed a HR of 3.26 (95% CI 1.54–6.90; P=0.002) in
univariate, and HR 4.08 (95% CI 1.79–9.28; P=0.001) in
multivariate analysis. In the multivariate analyses only lymph node
status (P=0.048) retained its significance in the presence of the 26-
probeset signature while age, tumor size, and histological grading
did not reach significance (Table 2).
Correlation of the prognostic signature scores with
molecular phenotypes in triple negative breast cancer
Several investigators described molecular subgroups within
TNBC defined by the variable expression of various metagenes
(i.e. average expression of highly co-expressed genes). In order to
examine if our TNBC-derived prognostic signatures correspond to
previously described metagenes that were used to subdivide
TNBC, we calculated the correlation between the our signature
scores and 16 different previously published TNBC-related
metagenes [9,10]. Figure S4 displays the results of hierarchical
clustering (based on Person correlation) of the 264-gene signature
score and the different metagenes. The highest correlation was
observed to the VEGF, Histone, and IL-8 metagenes in the finding
cohort (Figure S4 panel A). In the validation cohort, the Stroma and
Hemoglobin metagenes also clustered within this group (Figure S4
panel B). Of note however, these latter two metagenes are
associated with a high dataset bias (see Figure S5). A similar result
was obtained with the 26-probeset signature which is shown in
Figure S4 panel C and D. This signature also clustered together
with VEGF, IL-8, and Histone metagenes.
Correlation of individual markers from the prognostic
signatures with triple negative breast cancer metagenes
In order to examine if the individual genes that constitute the
TNBC-derived prognostic signatures correspond to the previously
described gene clusters within TNBC or represent new potential
markers, we also calculated the correlation between each individual
probeset from the supervised signatures and the 16 TNBC-related
Novel Prognostic Signatures for TNBC
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corresponding to the 264 probesets (235 associated with poor
prognosis and 29 with good prognosis in panel A and B,
respectively) and 16 metagenes in the 394 TNBC samples. The
highest correlation coefficient for each of the probesets and the 16
metagenes is given in Table S3. A correlation coefficient $0.2 was
used as threshold to assign a probeset to a specific metagene as
correlated (Figure S6 panel A and B). Sixty eight of the 264
probesets (25.8%) showed correlation ,0.2 to any metagene and
these were designated as ‘‘unclassified’’ (Figure S6 panel A;
alternatively we also applied a more stringent correlation coefficient
cutoff $0.3for a stability analysis which is shown in Figure S6 panel
C and D). Of the 235 probesets that were associated with a poor
prognosis, the largest probeset groups that were assigned to
metagenes included Stroma-related (n=51, 21.7%), Histone-related
(n=23, 9.8%), Molecular-Apocrine–related (n=21, 8.9%), Prolifera-
tion–related (n=17, 7.2%), and IL-8/inflammation–related (n=13,
5.5%) (Table S3 and Figure S6 panel A). In contrast 21 of the 29
probesets (72.4%) associated with good prognosis were assigned to
five metagenes each related to immune cell infiltration (B-cell, T-cell,
MHC-1, MHC-2, and IFN metagenes; Figure S6 panel B).
Correlation of the identified prognostic signature scores
with published gene signatures in breast cancer
Several gene signatures were previously described that are predictive
of prognosis of breast cancer in general. We also examined if our
TNBC-derived signatures represent a surrogate of these previously
reported breast cancer prognostic signatures including the recurrence
score [35], the genomic grade index [36], the 70-gene signature [37],
the wound response signature [38], the 7-gene immune response score
[39], the stroma derived prognosticpredictor[40], and a medullarylike
signature [18]. We assessed the correlation between our signatures and
these signatures in our finding cohort. Figure 3 shows hierarchical
clustering result of the 264-probeset signature score as continuous
variable and the 16 metagenes and the seven previously published
prognostic gene signatures. The recurrence score, the genomic grade
index, the wound response signature, and the 70-gene signature, all
clustered together with the proliferation and the basal-like metagenes.
This indicates that many of the genes included in these signatures are
related to proliferation. In contrast, the stroma derived prognostic
predictor, the 7 gene immune response score, and the medullary-like
signature clustered together with the different immune cell metagenes
in a second large cluster. None of these signatures were related to our
new TNBC-derived prognostic signature which clustered together with
the VEGF-, IL-8-, Molecular apocrine-, Claudin-CD24-, and Histone-
metagenes in a separate cluster (Figure 3). Similar results were obtained
when we used the smaller 26-probeset signature (Figure S7).
Predictive value of prognostic genes for response to
neoadjuvant chemotherapy in TNBC
We have previously shown that tumor infiltration by lympho-
cytes reflected in the high expression of B-Cell and T-Cell
Table 1. 26 probeset supervised prognostic signature for TNBC from SAM.
Affy_ID GeneSymbol SAM-Score direction of prognostic value (poor/good)
211506_s_at IL8 3.754 POOR
211708_s_at SCD 3.377 POOR
39249_at AQP3 3.308 POOR
202859_x_at IL8 3.299 POOR
202627_s_at SERPINE1 3.136 POOR
212909_at LYPDC1 3.118 POOR
200737_at PGK1 3.090 POOR
204344_s_at SEC23A 3.075 POOR
205810_s_at WASL 3.071 POOR
217356_s_at PGK1 3.031 POOR
215779_s_at HIST1H2BG 3.017 POOR
212344_at SULF1 3.008 POOR
209875_s_at SPP1 3.002 POOR
219434_at TREM1 2.982 POOR
219508_at GCNT3 2.966 POOR
208881_x_at IDI1 2.959 POOR
215427_s_at ZCCHC14 2.958 POOR
214603_at MAGEA2 2.956 POOR
219875_s_at PNAS-4 2.951 POOR
204083_s_at TPM2 2.948 POOR
218468_s_at GREM1 2.937 POOR
204615_x_at IDI1 2.902 POOR
212354_at SULF1 2.858 POOR
218469_at GREM1 2.836 POOR
212353_at SULF1 2.809 POOR
202497_x_at SLC2A3 2.797 POOR
doi:10.1371/journal.pone.0028403.t001
Novel Prognostic Signatures for TNBC
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probeset signature and the 26-probeset signature.
Finding Cohort Validation Cohort
Variable
No. of
patients
1
Hazard
Ratio 95% CI P-Value
{
No. of
patients
1
Hazard
Ratio 95% CI
P-
Value
{
264-probeset signature High vs Low* 59 vs 178 4.44 2.82–6.99 ,0.001 11 vs 85 4.03 1.71–9.48 0.001
Lymph node status LNN vs LNP 210 vs 27 0.73 0.38–1.40 0.341 55 vs 41 0.50 0.23–1.09 0.080
Age .50 vs #50 113 vs 124 0.73 0.47–1.15 0.176 60 vs 36 2.03 0.91–4.54 0.085
Tumor size #2c mv s.2 cm 72 vs 165 1.00 0.60–1.64 0.964 21 vs 75 0.94 0.36–2.47 0.899
Histological grading G3 vs G1&2 166 vs 71 1.13 0.69–1.87 0.622 71 vs 25 0.75 0.32–1.72 0.491
26-probeset signature High vs Low* 62 vs 175 3.76 2.38–5.94 ,0.001 15 vs 81 4.08 1.79–9.28 0.001
Lymph node status LNN vs LNP 210 vs 27 0.71 0.37–1.36 0.300 55 vs 41 0.45 0.21–0.99 0.048
Age .50 vs #50 113 vs 124 0.67 0.42–1.06 0.090 60 vs 36 1.87 0.84–4.16 0.125
Tumor size #2c mv s.2 cm 72 vs 165 0.96 0.58–1.58 0.860 21 vs 75 0.97 0.37–2.53 0.946
Histological grading G3 vs G1&2 166 vs 71 1.01 0.61–1.67 0.986 71 vs 25 0.68 0.29–1.59 0.372
1information on all parameters was available for 237 of the 297 TNBC samples with follow up data from the finding cohort and 96 of the 105 TNBC samples with follow
up data from the validation cohort.
{Significant P-Values are given in bold.
*highest quartile of expression score vs. rest (see Supplementary Table S4 for analysis of continous signature scores).
doi:10.1371/journal.pone.0028403.t002
Figure 2. Kaplan Meier analysis according to the prognostic signatures in the finding and validation cohort. A) The 394 TNBC samples
from the finding cohort were stratified according to the highest quartile of expression of the 264-probeset signature score. Kaplan Meier analysis of
event free survival of 297 samples with follow up information is shown. B) The 261 TNBC samples from the validation cohort were stratified according
to the highest quartile of expression of the 264-probeset signature score. Kaplan Meier analysis of event free survival of 105 samples with follow up
information is shown. C) The same analysis as in (A) was performed using the 26-probeset signature. D) The same analysis as in (B) was performed
using the 26-probeset signature.
doi:10.1371/journal.pone.0028403.g002
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chemotherapy [22]. This predictive value was observed for both
ER-positive and ER-negative cancers [22]. To test the potential
predictive value of our newly identified prognostic signatures we
assembled gene expression data from TNBC treated with
neoadjuvant chemotherapy encompassing 191 samples that also
had pathological complete response (pCR) data available (Table
S5). Figure 4A shows the results of receiver operator characteristics
(ROC) analyses for a previously published B-cell metagene which
has known predictive value and for the 26-gene TNBC-derived
prognostic signature. The area under the curve (AUC) for the B-
cell metagene was 0.606 (95% CI 0.512–0.699, P=0.025) and for
the 264-gene signature it was 0.588 (95% CI 0. 504–0.673,
P=0.061). A simple linear combination of both scores led to an
improved AUC of 0.656 (95% CI 0.568–0.743, P=0.001). A
similar but non-significant trend was seen in a separate 95 TNBC
samples from the TOP-trial [43] (Table S5). In this independent
validation dataset, the AUC of the B-cell metagene alone was
0.587 (95% CI 0.418–0.757, P=0.33; Figure 4B) and it was 0.621
(95% CI 0.446–0.797, P=0.175) for the combination of the 26-
probeset signature and the B-cell metagene.
Discussion
We identified two prognostic signatures including 264 and 26
probe sets each from gene expression data of triple negative breast
cancers (TNBC) using a supervised discovery method. The smaller
signature based on probe sets with the lowest false discovery rate
represent a subset of the larger signature. We validated the
independent prognostic value of both signatures in a separate
validation cohort both using the signatures as continuous scores
(P,0.0001; Table S4) as well as dichotomous variables (P=0.001;
Table 2). These gene signatures remained statistically significant
prognostic predictors in multivariate analysis that included age,
tumor size, nodal status and histologic grade. In order to develop
these signatures we used TNBC cases only. Previous attempts to
develop prognostic predictors almost invariable used mixed patient
cohorts [37,44,45,46,47,48,49,50]. The resulting signatures from
those studies have frequently mirrored the differences in prognosis
between molecular subtypes of breast cancer and were mainly
associated with ER status and proliferation [4]. Consequently our
new TNBC-derived prognostic signatures did not closely relate to
the published general prognostic signatures (Figure 3). In contrast,
the new signatures are mostly related to two metagenes which we
previously described in TNBC, the IL-8/inflammation and VEGF
metagenes. These metagenes were discovered through unsuper-
vised analysis of the same dataset and are based on strong and
consistent co-expression patterns and provided us with a tool to
subclassify TNBC in a previous publication [9,10]. Recent
laboratory studies have demonstrated that IL-8 could directly
increase the survival of breast cancer stem cells after chemother-
apy [51] which can be blocked with IL-8 directed drugs [52]. The
cytokine loops and cellular pathways regulated by IL-8 closely
resemble those activated during chronic inflammation and wound
healing which have previously been implicated in cancer [53].
A signature highly similar to our VEGF metagene was also
described in an independent dataset recently [31]. In that study
the VEGF metagene demonstrated high expression in metastatic
breast cancer samples and was significantly associated with poor
outcome in both breast and lung cancer and glioblastomas. These
observations are consistent with our findings. Interestingly many of
the genes included in VEGF metagene contain HIF1a binding
sites and are known to be transcriptionally regulated by this
hypoxia-induced factor and therefore may represent a molecular
measure of tumor hypoxia [31]. This raises the possibility that the
VEGF metagene and our prognostic signature that is related to it
may only be a surrogate of increasing tumors size. But this seems
not to be the case since we observed a negative correlation
between the prognostic signature and tumors size (Table S6).
The 264-probest signature contains 29 probesets (11.0%) which
were inversely associated with a poor prognosis and therefore we
refer to it as good prognosis genes. Twenty one of these (72.4%)
were correlated with immune cell metagenes which is consistent
with several other publications which have shown that lymphocyte
infiltration of TNBC is associated with an improved prognosis
[22,24,25,39,18]. Metagenes which serve as surrogate markers for
lymphocyte infiltration of the tumor (e.g. the B-Cell and T-Cell
metagenes) are also predictive of response to neoadjuvant
chemotherapy [22]. Therefore, we also assessed the chemotherapy
predictive value of our prognostic signatures and found that it had
only a week association with response to chemotherapy (Figure 4).
Our study has several limitations. The definition of TNBC was
based on gene expression data which is not the standard definition
used in the clinic. This definition holds the promise that samples
erroneously characterized as receptor-negative by immunohisto-
chemistry do not introduce noise into our analysis but discrepan-
cies to cohorts defined by immunohistochemistry can occur. We
found agreement of ER status between immunohistochemistry and
gene expression data for 444 (84.4%) of 526 samples (86.8% and
81.3% in the finding and validation cohorts, respectively). For PgR
status we found agreement for 407 (87.5%) of 465 samples (84.8%
and 90.5% in finding and validation cohort), and for HER2
agreement for 347 (94.3%) of 368 samples (94.4% and 94.1% in
finding and validation cohort). Agreement for the status of all three
receptors was found for 276 (76.2%) of 362 samples (78.7% and
Figure 3. Relationship of the 264 probeset signature to the 16
metagenes and seven known prognostic signatures in TNBC.
The 394 TNBC samples were analyzed for the expression of 16
metagenes and seven previously published prognostic signatures
(recurrence score, genomic grade index, 70-gene signature, wound
response signature, 7-gene immune response module, stroma derived
prognostic predictor, and a medullary like signature). Resulting
continous scores were used for hierarchical clustering using the
Pearson correlation as a distance metric. The mutual relationships of
all signatures is presented by the hierarchical dendrogram.
doi:10.1371/journal.pone.0028403.g003
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histological grading the proportion of grade 3 tumors is 73.5% and
74.1% in finding and validation cohort, respectively (Table S7).
These numbers are clearly smaller than 92–98% in previously
reported studies [8,54,55] indicating that the cohorts used in our
study may not be truly representative of triple negative breast
cancers in general. However despite the higher number of G1 and
G2 samples histological grading was not a significant factor for
survival in our cohort neither in multivariate nor univariate
analysis. Most TNBC are high grade and therefore grade is not as
important for prognosis in this subtype as it is in ER positive
disease. Age and tumor size were also not significant in our
cohorts, even in univariate analysis. TNBCs are also often
associated with younger age but the impact of age for prognosis
within this subtype is not yet fully clear. Several lines of evidence to
suggest that tumour size may not be prognostic in TNBC [8,56].
Still it cannot be excluded that a bias in our cohort is the reason
for the lack of significance of these factors.
Our analysis involved pooling of several datasets to increase
sample size and power for discovery and validation. This strategy
bears the risk of a confounding effect through systematic technical
differences that exist between individual datasets [57,58]. To
minimize this confounder we performed multiple filtering steps to
remove biased datasets and dataset-biased genes (see Methods). In
order to validate the robustness of the obtained results we also
performed a stability analysis by using different filtering cutoffs
(Figure S2). As shown in Figure S8 the validation of several
alternative signatures generated through a variety of filtering
combinations resulted in similar results in the validation cohort
indicating a robust finding. This study also has the limitation of
heterogeneous therapy of the cases included, some cancers were
treated with surgery alone others received adjuvant or neoadju-
vant chemotherapy of various types. This treatment heterogeneity
limits the clinical interpretation of the findings, however since the
prognostic signatures had limited predictive value for neoadjuvant
chemotherapy response, we infer that their outcome predictive
value is mostly derived from its prognostic components. However
the ‘‘good’’ prognostic group still has more than 20% recurrence
at 5 years. Thus this outcome would not change the actual clinical
management of this subset of patients but could help to develop a
clinically useful multivariate prognostic model for TNBC.
During the generation of this report Lehmann et al. [59]
described a similar strategy of a pooled dataset of TNBC samples
with microarray data. These authors identified seven different
TNBC subtypes by unsupervised k-means clustering. The
expression profiles of these subtypes are similar to many of the
metagenes that we have reported for TNBC [9,10]. Thus we
wondered whether our supervised signature would also correlate
Figure 4. Analysis of the predictive value of an immune cell metagene and the supervised prognostic signature for response to
neoadjuvant chemotherapy in TNBC. A) Neoadjuvant treated TNBC samples with information on pathological complete response (pCR) and
available Affymetrix expression data were assembled from 7 datasets (MDA133, GSE16716, GSE18728, GSE19697, GSE20194, GSE20271, Frankfurt-3).
Only pretherapeutic biopsies that were not microdissected were included (n=191 nonredundant samples) of which 52 (27%) experienced a pCR.
Three separate ROC curves for prediction of pCR by the B-Cell metagene, no-pCR by the 26-probeset signature, and pCR by a combination of both
gene signatures are shown. The areas under the curve (AUC) were 0.606, 0.588, and 0.656, respectively. B) The same analyses as presented in (A) were
performed using a smaller independent validation cohort of 95 TNBC from the TOP-Trial (GSE16446). AUC of 0.587, 0.603, and 0.621, respectively, and
only a trend towards significance (P=0.175) was observed in these data.
doi:10.1371/journal.pone.0028403.g004
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clear correlation of the supervised signature with any of these
seven subtypes described by Lehmann et al. was observed. We
have also analyzed whether our signature captures similar
information as the well known intrinsic molecular subtypes of
breast cancer [3,60]. To this end we used a recently published
implementation of different variants of the centroid method to
assign single samples to a molecular subtype [61]. The
corresponding results are shown in Table S8. We applied two
alternative variants of the method which both led to the conclusion
that no significant difference in subtype assignment was observed
when samples were classified according to the expression of the
264-probeset signature.
In our previous study [9] we had used unsupervised methods to
identify subgroups of TNBC without considering outcome in the
first place. Based on subsequent correlation of the obtained groups
with prognosis we then constructed a simple binary classifier from
expression of B-cell- and IL-8-metagenes. In contrast, the
supervised signature presented here seem to include information
from several additional biological characteristics. In fact this
supervised signature can outperform the simple combination of the
two parameters used in our previous study. However, the
interpretation of the biology of such an amalgamated signature
could be much more difficult than the interpretation of metagenes.
In summary, in this paper we demonstrated that the use of a
homogenous TNBC dataset allowed us to identify prognostic gene
signatures that are unrelated to previously published general breast
cancer prognostic signatures. The composition of the signature
suggests that IL-8 mediated inflammation and VEGF related
signaling herald very poor prognosis in TNBC and immune
infiltration predicts better outcome. These observations could also
suggest potential novel therapeutic strategies for these patients as
e.g. inhibiting IL-8 signalling [51,52] might be combined with
anti-angiogenesis therapies [31], and immune augmentation [10].
Supporting Information
Figure S1 Selection of the TNBC finding cohort from
multiple datasets based on dataset comparibility. Triple
negative breast cancers (TNBC, n=579) from 28 datasets were
sorted by dataset according to a dataset comparability metric
(horizontally). Shown are the full array data of normalized
Affymetrix U133A microarrays. The 15 most comparable datasets
encompassing n=394 TNBC samples were subsequently used as a
finding cohort and the remaining 13 datasets (n=185 TNBC
samples) withhold as validation cohort.
(PDF)
Figure S2 Analysis of a potential dataset bias among
probesets of the prognostic signatures from the super-
vised analysis. A) The standard Kruskal-Wallis rank test was
used to analyze the dependence of each individual probesets’
expression on the vector of the 15 different datasets in the finding
cohort of n=394 samples. The distribution of the rank sum
statistics for all 22,283 probesets from the U133A array is shown.
Two dotted vertical lines mark the used cutoff values of 75 (yellow)
and 150 (red). B) Distribution of the Kruskal-Wallis rank sum
statistics for the 235 probesets identified by SAM as associated
with poor prognosis. Used cutoffs are represented by dotted
vertical lines as in (A). C) Distribution of the Kruskal-Wallis rank
sum statistics for th 29 probesets identified by SAM as associated
with good prognosis. Used cutoffs are represented by dotted
vertical lines as in (A).
(PDF)
Figure S3 Kaplan Meier analysis of quartiles according
to the prognostic signature scores in the finding and
validation cohorts. A) The 394 TNBC samples from the
finding cohort were stratified according to quartiles of expression
of the 264-probeset signature score. Kaplan Meier analysis of
event free survival of 297 samples with follow up information is
shown. B) The 261 TNBC samples from the validation cohort
were stratified according to quartiles of expression of the 264-
probeset signature score. Kaplan Meier analysis of event free
survival of 105 samples with follow up information is shown. C)
The same analysis as in (A) was performed using the 26-probeset
signature. D) The same analysis as in (B) was performed using the
26-probeset signature.
(PDF)
Figure S4 Correlation of the prognostic signatures with
metagenes for molecular phenotypes in triple negative
breast cancer. A) The continous score of the 264-probeset
signature was correlated with the expression of 16 metagenes for
molecular phenotypes in the 394 TNBC samples from the finding
cohort. Shown is the result from hierarchical average linkage
clustering based on absolute Pearson correlation. The signature
score clustered together with VEGF, Histone, and IL-8 metagenes.
B) The same analysis as in (A) was performed in the validation
cohort of 261 independent TNBC samples. In this analysis the
signature score clustered together with Stroma, Hemoglobin,
VEGF, and IL-8 metagenes. Of note, however, Stroma and
Hemoglobin metagenes are associated with a high dataset bias (see
Supplementary Figure S5). C) The same analysis as in (A) was
performed with the 26-probeset signature in the 394 TNBC
samples from the finding cohort. The 26-probeset signature which
was obtained by higher stringency in SAM analysis clustered
together with IL-8, VEGF, and Histone metagenes. D) The same
analysis as in (C) was performed with the 26-probest signature in
the validation cohort of 261 samples. Similar as in (C) the 26-
probeset signature clustered together with VEGF, IL-8, Prolifer-
ation, and Histone metagenes.
(PDF)
Figure S5 Analysis of dataset bias of metagenes and the
prognostic signatures. A) The dependence of earch probeset
from the U133A array on the dataset vector was analyzed using
the standard Kruskal-Wallis rank test in the finding cohort of 394
samples (see Suppl. Fig. S2). Box plots are shown for the Kruskal-
Wallis statistics of the probesets of each metagene on the left and
for the two prognostic signatures on the right. The highest dataset
bias was observed for Stroma and Hemoglobin metagenes which is
related to different applied biopsy methods (fine needle biopsy vs.
surgical resection). B) The 261 samples from the validation cohort
were used to calculate the Kruskal-Wallis rank sum statistics for all
probesets. Again box plots are shown as in (A), but the Kruskal-
Wallis statistics from the validation cohort were applied. Several
metagenes are characterized by higher bias in the validation
cohort.
(PDF)
Figure S6 Correlation of individual markers from the
prognostic signatures with known metagenes in triple
negative breast cancer. From the 264 Affymetrix probsets of
the supervised prognostic signature, 235 probesets were associated
with poor prognosis (analyzed in panels A and C) and 29 with
good prognosis (analyzed in panels B and D). A) The 235
individual probesets associated with poor prognosis (horizontically)
were analyzed for their correlation with the expression of 16
metagenes (vertically) for molecular phenotypes in the 394 TNBC
samples from the finding cohort. 116 probesets displaying a
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on the left according to the assigned metagene while 60 probesets
remained unclassified. B) The 29 individual probesets associated
with good prognosis were analyzed as in (A) and 21 assigned to
metagenes (cutoff 0.2) are sorted horizontically on the left while 8
remained unclassified. C) The same analysis as in (A) was
performed using the more stringent cutoff 0.3 for assignment to
a metagene resulting in 118 probesets correlated to metagenes
from the list of 235 probesets associated with poor prognosis. D)
The same analysis as in (B) was perfomed using the more stringent
cutoff 0.3 resulting in 18 of the 29 good prognosis probesets
assigned to metagenes. All individual correlation values are given
in Supplementary Table S3.
(PDF)
Figure S7 Relationship of the 26 probeset signature to
the 16 metagenes and seven known prognostic signa-
tures in TNBC. The 394 TNBC samples were analyzed for the
expression of 16 metagenes and seven previously published
prognostic signatures as described in Figure 3 and hierachical
clustered using Pearson correlation as distance metric. Abbrevi-
ations: SAMmean=26 probeset signature wound.score$score=
Wound response signature rs.394$score=recurrence score ggi.
score$score=genomic grade index gene70.score$score=70-gene
signature sabatier.score$score=medullary like signature Tesch7.
score$score=7-gene immune response module sdpp.sore$score=
stroma derived prognostic predictor.
(PDF)
Figure S8 Stability analysis of the prognostic signatures
from the supervised analysis. The 264 Affymetrix probsets of
the supervised prognostic signature were filtered according to their
dataset bias measured through Kruskal-Wallis statistic and
different stringency from SAM analysis as given in the Table
below the graphs. The resulting probeset lists of 252, 24, 181, and
16 probesets were used for prognostic signature generation as the
original 264 probeset list. In upper panels A, B, C, and D the
correlation of the four alternative signatures to the 264-probeset
signature is shown by scatter plot analysis. The lower panels
display the results from the Kaplan-Meier analyses of the
validation cohort of 261 TNBC (105 samples with follow up
information). In addition P-Values of multivariate Cox regression
analysis of the validation cohort using continous signature scores
are given in the table below.
(PDF)
Figure S9 Expression of the 264-probeset and 26-
probeset signature scores in seven different TNBC
subtypes according to Lehmann et al. A) Box plots
comparing the expression of the 264-probeset signature in the
seven different TNBC subtypes according to Lehmann et al. (J
Clin Invest. 2011; 121: 2750) separately for our finding and
validation cohorts. No clear correlation of the expression of the
signature with any of the subtypes was observed. The seven
subtypes have been ordered according the expression of the
signature in the finding cohort. Highest expression was observed in
the ‘‘basal-like 2’’ (BL2) and ‘‘luminal androgen receptor’’ (LAR)
subtypes of the finding cohort. However this effect was not
reproduced in the validation cohort. B) The same analysis as in (A)
was performed for the expression of the 26-probeset signature.
The observed result was similar in that no reproducible correlation
of the signature with any subtypes was detected.
(PDF)
Table S1 Summary of Affymetrix microarray datasets
used in this study.
(PDF)
Table S2 List of 355 Affymetrix probesets used for
metagene calculation.
(PDF)
Table S3 Details of probesets from the supervised
signatures.
(XLS)
Table S4 A) Multivariate Cox regression of continous
264-probeset signature and standard parameters for
event free survival in the finding cohort B) Multivariate
Cox regression of continous 26-probeset signature and
standard parameters for event free survival in the
finding cohort.
(PDF)
Table S5 Pre-therapeutic samples from neoadjuvant
treated TNBC.
(PDF)
Table S6 Clinical parameters of TNBC according to
expression of the 264-probeset signature.
(PDF)
Table S7 Histological grade among samples in the
finding and validation cohort.
(PDF)
Table S8 Distribution of intrinsic molecular subtypes
according to expression of the 264-probeset signature in
TNBC.
(PDF)
Table S9 264 probeset supervised prognostic signature
for TNBC from SAM.
(PDF)
Data S1 R script of the analyses.
(R)
Data S2 R.Data file (contains 11 data objects used in the R
script from Data S1).
(7z)
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